LEGN Legend Biotech Corporation Quarterly EPS earnings growth

Official company branding of Legend Biotech Corp. (LEGN)

Legend Biotech (LEGN) price action is driven by the implementation rates of innovative therapies and the expansion of laboratories. Quarterly EPS variability clearly demonstrates these processes, and the metric has now reached the level of 124.50. However, the high cost of CAR-T production and dependence on J&J create risks. The high barrier to entry is driven by strict government regulation and the costs of bioengineering research.

Legend Biotech Corporation (LEGN) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/10/2026

Legend Biotech Corp. (LEGN) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Price Legend Biotech Corporation|LEGN - Consensus Target
- market capitalization data:
Market Capitalization Legend Biotech Inc.|LEGN - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Legend Biotech|LEGN - Company Book Value|Market Value to Book Value Ratio legendbiotech.com|LEGN - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Equity Ratio Legend Biotech|LEGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Legend Biotech|LEGN - Company Total Indebtedness|Debts to Book Capitalization Legend Biotech Inc.|LEGN - Long-Term Debt|Company Short-Term Debt Legend Biotech|Quick Ratio legendbiotech.com
- earnings and market multiples details:
LEGN - Company Net Income|Future Profit Legend Biotech|LEGN - Company Value to Net Income|Projected Price to Earnings Legend Biotech Inc.|LEGN - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Legend Biotech Inc.|LEGN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Legend Biotech|LEGN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months legendbiotech.com|LEGN - Earnings per share increase in current year|Earnings growth forecast for next year Legend Biotech
Fundamental company analysis:Legend Biotech Corporation - LEGN
Finished products of Legend Biotech Corp.

The market values Legend Biotech (LEGN) through the lens of its innovation scalability. This indicator captures the percentage change in net earnings per share between consecutive quarters. By analyzing the quarterly earnings per share chart on GURU.Markets, an investor can observe the real-time monetization dynamics. For Legend Biotech (LEGN), this pace depends directly on the efficiency of external GMP manufacturing facilities. Stable growth confirms the resilience of the cell therapy outsourcing model.

Analysis of competing companies

SANA: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Autolus Therapeutics PLC|ALLO (Allogene Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Selecta Biosciences Inc. RNAC|Year-over-year earnings per share growth for the last twelve months Cellectis S.A. (CLLS)|Year-over-year earnings per share growth for the last twelve months CRBU (cariboubio.com)|Year-over-year earnings per share growth for the last twelve months Instil Bio TIL|Genenta Science SpA - Year-over-year earnings per share growth for the last twelve months|IPSC: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months JSPR (Jasper Therapeutics)|SNTI: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Adaptimmune Therapeutics ADAP|CERO (CERo Therapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alaunos TCRT|Year-over-year earnings per share growth for the last twelve months Achilles Therapeutics (ACHL)|CARGO Therapeutics, Inc - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PSTX (Poseida Therapeutics)|2seventybio.com (TSVT) - Earnings per share growth in annualized terms for the last twelve months|GRCL: Year-over-year net earnings per share growth for the last 12 months